Correction to: Osteoporos Int
In the Antifracture Treatment in Men with Osteoporosis section of this article, the sentence that begins: "Medications currently FDA approved for osteoporosis treatment in men," should have excluded "abaloparatide," which is not FDA approved for prevention or treatment of osteoporosis in men.
In the Administration section for Alendronate, the sentence that begins "Oral alendronate (generic and Fosamax®) tablets" should state that tablets must be taken at least 30 min before the first food, beverage, or medication of the day with plan water only.
In the Administration section for Risedronate, the sentence that begins "After taking risedronate," should state that patients must remain upright and wait at least 30 min before eating, drinking, or taking any other medication.
In the Administration section for Risedronate, the sentence that begins “As with standard-release risedronate," should read “Oral delayed-release risedronate (Atelvia®) is taken not on an empty stomach, but directly after breakfast with ≥ 4 oz of plain water (no other liquid).”
The original article has been corrected.
Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
